Emerging Growth Biotech Stocks
Now, due to “regulatory uncertainties” and the time and resources needed to provide the additional data, Merck said it decided to discontinue the development of the drug and instead focus its efforts on advancing its other Covid-19 drug as well as accelerating production of the Johnson & Johnson vaccine.
Halberd (HALB) Antibodies Shown To Be Effective Against Multiple Covid-19 Mutations
The rate of new U.S. coronavirus cases remains elevated as the country tries to ramp up its vaccination campaign following the distribution halt of Johnson & Johnson’s Covid-19 vaccine.The country is reporting about 71,200 new Covid cases per day, based on a seven-day average of data from Johns Hopkins University.
Spun off from Abbott Labs in 2013, AbbVie is one of the newer pharmaceutical companies on the market. However, the young company's management team wasted no time developing breakthrough drugs and driving sales to generate huge returns for shareholders.
So far in 2021 Avalon GloboCare (NASDAQ:AVCO) has advanced there research platform substantially by expanding a Co-Development program with MIT using CRISPR based genome editing to combat cancer metastasis.
“As it was for many companies, 2020 was a challenging year for us,” commented Marco Alfonsi, Can B’s Chief Executive Officer. “We took the time to right-size our expenses, focus our energy on higher margin revenue opportunities and improve our positioning for future growth and profits.”
Multicorp (MCIC) Announces Change in Corporate Operations
Miami, FL – March 31, 2021 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled...
CytoDyn Inc. (OTCMKTS: CYDY) just released stunning numbers which takes the company down one of two roads. The first road is a quick review by the FDA...